EVs from the PB of newly diagnosed multiple myeloma (NDMM) patients had a lower level of CD38 (median MFI = 610.45), but not significantly different from patients who had received DARA, p = 0.07, however it should be noted that the sample size of NDMM is only four patients. This evidence concerns the gene CD38 and plasma cell myeloma.